Lexaria’s DehydraTECH™ Overcomes Key Hurdles for Cannabis Extracts
June 26th, 2018
Exclusive, News, Top News
Cannabis oils and extracts have become tremendously popular following the legalization of medical and recreational cannabis across a growing number of jurisdictions. In addition to avoiding the health risks of smoking, cannabis oils and extracts enable patients and consumers to access precise dosing across a wide range of delivery systems (e.g. capsules, vape oil, or edibles) for a consistent experience every time.
Lexaria Bioscience Inc. (OTCQX: LXRP) addresses these shortcomings with its DehydraTECH™ drug delivery platform. By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the bitter and earthy taste of cannabis oil and ensures quick and effective transportation into the bloodstream without degradation in the stomach or liver. Lexaria’s technology now has over 40 patents pending and four patents already granted in the US.
Masking Poor Taste
The taste of cannabis oils and extracts depends on the process used to extract the cannabinoids from the plant but it’s generally described as earthy and bitter. In fact, new patients and consumers commonly ask how they can mask the taste of the drug. Many people recommend taking cannabis oils and extracts with breath mints or other products, but the process can be inconvenient at best and ineffective at worst.
Lexaria’s DehydraTECH™ technology masks the earthy and bitter flavors of cannabis oils and extracts using fatty acids. These fatty acids are believed to block and shunt bound ingredients away from bitter taste receptors, which eliminates the bad taste in products that incorporate the technology. Non-active ingredients can then be added to re-flavor the cannabis oils and extracts to make them more palatable for patients and consumers.
For example, Nuka Enterprises LLC signed a licensing agreement earlier this year for its cannabis-infused line of chocolates and edible products. The company had already been utilizing Lexaria’s technology in its award-winning 1906 brand of chocolates for about two years to mask cannabis flavors and ensure a great taste — along with the many other benefits of Lexaria’s DehydraTECH™ platform.
Cannabinoids have poor bioavailability for a couple different reasons: Orally-consumed cannabinoids are largely destroyed by stomach acids, and those that aren’t are broken down and altered by first pass metabolism in the liver. This is why smoking cannabis has a much more immediate effect than orally-consumed cannabis; it avoids first-pass metabolism and is more quickly absorbed into the bloodstream through the lungs.
Lexaria’s DehydraTECH™ technology protects orally-consumed cannabinoids during the stomach transit by co-joining them with lipids. At the same time, the long-chain fatty acids bypass first pass liver metabolism by design, enabling the cannabinoids to remain intact upon delivery to the bloodstream. These two features help increase the bioavailability of cannabinoids and ultimately make them more effective for medical cannabis patients or recreational users, and also allow the edible experience to more closely mimic the smoked experience, for the first time ever.
Management has found that DehydraTECH™ reduces the onset time for cannabis oils and extracts to just 15 to 20 minutes compared to 60 to 120 minutes for traditional oral cannabinoids. At the same time, bio absorption improves by five to 10 times to match that of inhaled cannabinoid delivery mechanisms. These attributes make the technology ideal for medical uses cases where precise dosing and immediate onset are critical.
Lexaria’s technology has been repeatedly evaluated by invivo, invitro and human studies and is currently undergoing additional evaluation by Canada’s National Research Council.
Lexaria Bioscience Inc. (OTCQX: LXRP) represents a compelling investment opportunity in the cannabis industry and beyond. With its innovative DehydraTECH™ platform, the company solves many of the key shortcomings of oral cannabinoids and makes cannabinoid products for both medical and recreational consumers a lot more palatable and effective.
For more information, visit the company’s website at www.lexariabioscience.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.